December 27, 2017
Rose
Digital health in pharma definitely had a milestone moment in the fourth quarter with the FDA approval of Abilify MyCite, a new, sensor-enabled version of Otsuka’s drug for schizophrenia powered by Proteus Digital Health’s ingestible sensor technology. In addition to that, the quarter saw numerous other moves by pharma companies around clinical trials, chronic disease management, mental health, and, more generally, innovation.
from MobiHealthNews http://ift.tt/2pKxDfq
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment